Article
A novel selective ERK1/2 inhibitor, Laxiflorin B, targets EGFR mutation subtypes in non-small-cell lung cancer.
Acta pharmacologica Sinica - 1 Feb 2024
Chiang Cheng-Yao, Zhang Min, Huang Junrong, Zeng Juan, Chen Chunlan, Pan Dongmei, Yang Heng, Zhang Tiantian, Yang Min, Han Qiangqiang, Wang Zou, Xiao Tian, Chen Yangchao, Zou Yongdong, Yin Feng, Li Zigang, Zhu Lizhi, Zheng Duo
Abstract excerpt
Extracellular regulated protein kinases 1/2 (ERK1/2) are key members of multiple signaling pathways, including the ErbB axis. Ectopic ERK1/2 activation contributes to various types of cancer, especially drug resistance to inhibitors of RTK, RAF and MEK, and specific ERK1/2 inhibitors are scarce. In this study, we identified a potential novel covalent ERK inhibitor, Laxiflorin B, which is a herbal compound with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.